Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss how differences in patient populations across the MajesTEC clinical program may influence treatment decisions in relapsed/refractory multiple myeloma (RRMM).
The conversation focuses on the distinctions between heavily pretreated, triple-class-exposed patients and those treated earlier in the disease course, as well as the impact of anti-CD38 exposure versus true anti-CD38 refractoriness.
Dr. Huff reviews how emerging data support the use of BCMA-directed therapies across diverse patient populations, including those with prior anti-CD38 treatment exposure.
Dr. Mewawalla discusses how definitions of refractoriness influence her selection of combination versus monotherapy approaches and highlights the importance of tailoring treatment strategies based on prior response patterns.
The panel also explores ongoing questions regarding retreatment strategies, clonal disease evolution, and the potential role of anti-CD38 therapy in later lines of treatment.
Overall, the discussion emphasizes the importance of individualized treatment selection and careful interpretation of clinical trial data when managing patients with RRMM.
